Quarterly ResultMay 12, 2026, 07:47 AM
Coya Therapeutics Q1 Net Loss Per Share $(0.32); Cash $50.7M
AI Summary
Coya Therapeutics reported a net loss of $(7.21) million for Q1 2026, an improvement from $(7.31) million in Q1 2025, with net loss per share improving to $(0.32) from $(0.44). Collaboration revenue remained stable at $0.25 million. The company's cash and cash equivalents increased to $50.7 million as of March 31, 2026, primarily due to a $11.1 million private placement in January 2026. Coya expects its current cash to fund operations for at least one year, despite an accumulated deficit of $69.2 million.
Key Highlights
- Net loss per share improved to $(0.32) in Q1 2026 from $(0.44) in Q1 2025.
- Net loss was $(7.21) million in Q1 2026, compared to $(7.31) million in Q1 2025.
- Cash and cash equivalents increased to $50.7 million as of March 31, 2026.
- Collaboration revenue was $0.25 million in Q1 2026, down from $0.26 million.
- Raised $11.1 million gross proceeds from a private placement in January 2026.
- Research and development expenses decreased to $4.10 million from $5.21 million.
- General and administrative expenses increased to $3.78 million from $2.71 million.
- Accumulated deficit reached $69.2 million as of March 31, 2026.